Assertio Therapeutics, Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Operating Activities
Net (loss) income
Adjustments for non-cash items:
Depreciation and amortization
Amortization of investments
Accretion of debt discount and debt issuance costs
Convertible debt
Senior Notes
Total accretion of debt discount and debt issuance costs
Provisions for inventory and other assets
Loss on impairment of intangible asset
Loss (gain) on disposal of equipment
Stock-based compensation
Accretion of debt discount
Deferred income taxes
Intraperiod tax allocations
(Gain) loss on debt extinguishment and prepayment
Senior Notes
Total (Gain) loss on debt extinguishment and prepayment
Recurring fair value measurement of assets and liabilities
Gain on divestiture of Lazanda
Acquired in-process research and development
Excess tax benefit from stock-based compensation
Other
Changes in assets and liabilities:
Accounts receivable
Receivables from collaborative partners
Inventories
Prepaid and other assets
Income taxes receivable
Accounts payable and other accrued liabilities
Accrued rebates, returns and discounts
Interest payable
Accrued compensation
Income taxes payable

Net cash (used in) provided by operating activities
Acquired in-process research & development expense
Net cash provided by operating activities

Investing Activities
Purchases of property and equipment
Acquisition of a business
Acquisition of in-process research and development
Investment in convertible instrument
Proceeds from disposal of property and equipment
Purchases of marketable securities
Proceeds from sale of other assets
Maturities of marketable securities
Sales of marketable securities
Net cash (used in) provided by investing activities

Financing Activities
Proceeds from issuance of Senior Notes
Senior Notes issuance costs
Payment of contingent consideration liability
Repayment of Senior Notes
Fees for modification of Senior Notes
Convertible notes issuance costs
Senior Notes
Total convertible notes issuance costs

Proceeds from issuance of common stock
Excess tax benefit from stock-based compensation
Net cash (used in) provided by financing activities
Shares withheld for payment of employee's withholding tax liability
Net cash used in financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of period
Supplemental Disclosure of Cash Flow Information
Net cash paid (received) for income taxes
Net cash received for income taxes
Cash paid for interest
Non-cash consideration for in-process research and development
Accrued research and development
Capital expenditures incurred but not yet paid

Comments